Navigation Links
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Date:11/20/2008

illin Resistant Staphylococcus aureus (HA-MRSA) Overview. Available at http://www.cdc.gov/ncidod/dhqp/ar_MRSA.html. Accessed October 22, 2008.

(ii) Centers for Disease Control and Prevention Web site. Community-Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) Overview. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html. Accessed October 22, 2008.

(iii) Sakoulas, G et al. Clinical Infectious Diseases 2006; 42: S40-S50.

(iv) Tenover F, Moellering RC Jr. Clinical Infectious Diseases 2007; 44: 1208-15.

(v) Centers for Disease Control and Prevention Web site. S. aureus and MRSA Surveillance Summary 2007. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_surveillanceFS.html. Accessed October 22, 2008.

(vi) Kuehnert MJ et al. Emerging Infectious Diseases 2005; 11: 868-72.

(vii) Klevens, RM et al. Journal of the American Medical Association. 2007; 298: 1763-71.

    Media contacts:

    Dr Jürgen Raths, President and CEO                Tel: +41-61-417-96-60
    Harry Welten, MBA, CFO and Senior Vice President  Tel: +41-61-417-96-65
    Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... will do whatever needs to be done. ,Whether it be vitamins, ... smoke, ready to set ,aside their habit or smokers who live ... ,hold for the sake of the child? ,A statistics that ... Control Committee was ,that// Baxter County has the highest rate of ...
... country reported a new suspected case of the disease fears ... hours after doctors gave the cleared a woman suspected of ... worker was immediately admitted to a hospital after he arrived ... cough and cold similar to those of the deadly SARS ...
... the 2003 Annual Meeting of the American Association for Cancer ... effective means of cancer prognosis than measuring body mass index ... of the measures for detecting breast cancer are perfect, says ... ,But, he says that levels of leptin which ...
... that Men who smoke more than 20 cigarettes a day run ... the brain. Researchers had already identified a link between ischemic stroke ... brain - and smoking. The new study that covered 22,022 male ... to those who// had never smoked, men who smoked less than ...
... have told for a long time now a lot of ... lot of water. It has been advised we should,drink at ... sure we are,adequately hydrated. Researchers from Center for Human Nutrition ... beverages will also,help us keep ourselves hydrated.// A group of ...
... University of Wisconsin have reported that those who suffer,from ... can now get,relief through a patch of Capsaicin, the ... zoster virus, which also causes chicken pox.,Shingles results in ... the body and,the pain can persist even after the ...
Cached Medicine News:
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... absorbable collagen hemostat. FirstStop is a non-friable, ... removal characteristics. It can easily be cut ... wound. FirstStop products are not dispersed when ... after hemostasis is achieved. As the collagen ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: